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Introduction
Depression is up to 2–3 times more common in patients with 
cardiometabolic diseases such as coronary heart disease (CHD), 
diabetes and stroke, as compared to its prevalence in the general 
population.[1‑3] Prevalence estimates of  depression vary from 
15% to 25% in patients with cardiometabolic diseases such as 
CHD, diabetes and previous stroke.[4‑6] Depression, co‑morbid 
with these cardiometabolic diseases, has detrimental effects 
on mortality, clinical outcomes, treatment adherence and 
functional outcomes such as the ability to carry out activities 
of  daily living.[5,7‑10] Barth et al. reported in a meta‑analysis of  
20 studies that the risk of  death in patients with depressive 
symptoms and CHD was 2 times higher compared to risk of  
death in patients with CHD and no depressive symptoms (odds 
ratio [OR], 2.24; 95% confidence interval [CI] 1.37–3.60).[9] 
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AbstrAct
Background: Evidence on the long‑term usefulness of anti‑depressants in managing depression in cardiometabolic disease is 
limited. Aim: We examined the effects of anti‑depressant prescribing on depressive symptoms at 12 months follow‑up in patients 
with cardiometabolic disease and a positive depression screening result at baseline. Design and Setting: We retrospectively 
reviewed routine UK primary care data for patients with coronary heart disease, diabetes and previous stroke for the year 
2008–2009. 35,537 patients with one of the three above diseases underwent depression screening using the Hospital Anxiety 
and Depression Scale (HADS‑D). Of 7080 patients with a positive screening result (HADS‑D ≥ 8), 3933 (55.5%) patients had a 
repeat HADS‑D recorded at 12 months follow‑up. Methods: We compared the change in HADS‑D at follow‑up and remission 
rate in those who were prescribed anti‑depressants (n = 223) against those who were not (n = 3710). Results: The mean 
change in HADS‑D from baseline, for the nonprescribed group was similar to the reduction observed in patients who were 
continuously prescribed (n = 93) with anti‑depressants during follow‑up. Patients who were prescribed intermittently (n = 72) 
or only one (n = 58) prescription during follow‑up had a lower reduction in HADS‑D compared to the nonprescribed group. 
There was no difference in remission rates between continuously prescribed and the nonprescribed group, but remission was 
lower in patients prescribed intermittently and single prescription. Conclusion: Improvement in depressive symptoms in 
patients with cardiometabolic disease at 12 months was not any better in patients prescribed with anti‑depressants compared 
to the nonprescribed group. The role of anti‑depressants in the management of depression in cardiometabolic disease merits 
further investigation.
Keywords: Anti‑depressants’ effectiveness, anti‑depressants’ efficacy, coronary heart disease, cardiometabolic disease, 
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A review assessing poststroke mortality reported increased odds 
(OR 1.22, 95% CI 1.02–1.47) for a period of  2–5 years among 
patients with depressive symptoms based on findings from 13 
studies.[11] Another meta‑analysis has reported that the prevalence 
of  co‑morbid depression with diabetes is associated with a 
variety of  diabetes complications such as diabetic retinopathy, 
nephropathy, neuropathy, macrovascular complications, and 
sexual dysfunction.[12] In Scotland, 5.6% of  the adult population 
suffers from diabetes while 8.3% suffer from either CHD or 
previous stroke.[13] Based on previous findings, the reported 
prevalence rate of  depressive symptoms in this group of  patients 
is 19.9% in Scotland, which is similar to prevalence rates in other 
countries.[14]
Considering the increased prevalence and associated 
complications, the American Heart Association Science Advisory 
recommended routine depression screening for all patients with 
CHD in 2008.[15] In UK, the National Institute of  Health and 
Clinical Excellence recommends that depression screening in 
any chronic disease group should be targeted toward high‑risk 
patient groups.[16] The rationale of  depression screening in 
patients with cardiometabolic disease and co‑morbid depression 
is to facilitate early identification and initiation of  appropriate 
treatment. The major drawbacks of  the current evidence 
on use of  anti‑depressants in treatment of  depression with 
cardiometabolic diseases include little availability of  data on 
effectiveness (anti‑depressants leading to complete remission 
of  depressive symptoms) and dearth of  evidence on longer 
follow‑up (>6 months). There have been only four trials looking at 
the remission rates resulting from the use of  anti‑depressants for 
depressive symptoms in patients with CHD),[17,18] with three trials 
investigating outcomes at duration of  follow‑up <6 months[19‑21] 
and one trial looking at 18 months follow‑up.[22] The evidence 
for patients with depression symptoms in diabetes is similar,[23,24] 
with four trials examining remission rates[25‑28] and one of  them 
looking at follow‑up duration of  52 weeks.[28] For patients with 
poststroke depression,[29] the remission rate was examined for 
five trials but no data on longer follow‑up.
In this paper, we describe how we used a large primary care cohort 
to examine the effects, if  any, of  anti‑depressant prescribing on 
depression symptom scores at 12 months follow‑up, in patients 
with chronic disease and a positive depression screening result, 
at baseline.
Methods
Ethics statement
We received approval from the West of  Scotland Research 
Ethics Committee to undertake this work. The work involved 
retrospective analysis of  a large routinely collected dataset which 
was completely anonymized and the research team did not have 
access to patient identifiers, hence individual patient consent 
was not obtained. NHS Greater Glasgow and Clyde enhanced 
services data group, which was the authorized “guardian” of  this 
data set, granted the permission to analyze the data.
Study design and participants
The data reported in this paper comes from the West of  Scotland, 
with a population of  circa 1.8 million served by two different 
health boards. The local health boards oversee a program of  
incentivized depression screening in chronic disease as part 
of  a wider chronic disease management program of  “local 
enhanced services” (LES). These are contractual arrangements 
at a local health board level, which family practices can opt 
into and are designed to augment the basic quality outcomes 
framework (QOF) specification by incentivizing additional 
indicators that are deemed to be particularly important for a 
given geographical area. The QOF is part of  UK wide, pay for 
performance, General medical services contract for primary care 
physicians.[30] General practices in the health boards were paid 
under the LES scheme to carry out a comprehensive annual 
health assessment, which included depression screening using the 
Hospital Anxiety and Depression Score‑depressive subscale or 
HADS‑D,[31] for all patients with three common cardiometabolic 
conditions, CHD, diabetes, and stroke. This included all patients 
with three cardiometabolic conditions, irrespective of  whether 
they were incident or prevalent cases and their treatment status. 
The annual health assessment was usually carried out by a practice 
nurse and lasted approximately 1 h.
We anonymized the routinely collected data returned from the 
health assessments and used it for this study with permissions 
from NHS Greater Glasgow and Clyde enhanced the services 
data group. We restricted our analysis to adults aged from 18 to 
90 and health assessments recorded between April 01, 2008 and 
March 31, 2009. A total of  125,143 patients were listed as having 
at least one of  the three diseases‑CHD, diabetes or stroke in the 
year 2008–2009, and they all underwent a comprehensive health 
assessment during the observation period in the “DepChron” 
dataset.[14] Of  the total sample, 10,670 (8.5%) patients were 
under treatment for depression and were thus exempt from 
screening. The remaining 114,473 (91.5% of  total sample size) 
patients were eligible for depression screening. However, the 
uptake of  depression screening was poor and only undertaken in 
35,537 (31.1% of  those eligible). We analyzed the health assessment 
records between April 01, 2009 and March 31, 2010 to look at 
12 months follow‑up HADS‑D, for those who were screened in 
the 1st year of  study and noted to have a positive HADS‑D score.
Measurement of variables
The HADS‑D gives a total score of  0–21, we used a threshold 
of  ≥8 to define the presence of  depressive symptoms, as 
endorsed by national guidelines.[32] We calculated the change in 
HADS‑D using the respective scores for the 1st year (2008–2009) 
and for the 2nd year (2009–2010) of  health assessments. We 
analyzed the prescription records for patients who were screened 
and noted to have depressive symptoms between the dates of  
first and second assessment, which gave a follow‑up duration 
of  approximately 12 months. We excluded amitriptyline from 
the list of  anti‑depressants as it is often prescribed for other 
indications like chronic pain.
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We divided patients into four prescription groups based on 
the pattern of  prescribing described in their medical records: 
Continuous prescription group (anti‑depressants prescribed 
without a break, single prescription group (only one prescription 
of  anti‑depressant recorded in the observation period) 
intermittent group (anti‑depressants prescribed with a gap 
between two prescriptions of  anti‑depressants longer than 
3 months), and no anti‑depressant prescriptions.
We used the area based Scottish Index of  Multiple 
Deprivations (SIMD) as a measure of  socioeconomic 
status.[33] The SIMD score was divided into quintiles from 1 
to 5 with Q1 representing the most deprived area. Number of  
co‑morbid conditions (range: 1–3) represented a combination 
of  one or more of  the three cardiometabolic diseases under 
investigation: CHD, stroke or diabetes. Smoking status was 
divided into current nonsmokers and smokers; alcohol status 
was classified into moderate (<21 units men, <14 units women), 
hazardous (21–50 units men, 14–35 units women) and harmful 
(>50 units men, >35 units women) based on their weekly units 
consumption; this classification was adapted from the latest 
report of  the Scottish Health Survey.[34]
Statistical analysis
We used multiple linear regression with mean and standardized 
change (one standard deviation), with 95% CIs, in HADS‑D 
in year 2 from baseline (year 1) as the outcome variable; this 
was used as a proxy measure of  efficacy for anti‑depressant 
treatment. The anti‑depressant treatment category based on 
their prescription pattern described above was entered as a 
predictor variable, and the nonprescribed group was used as 
the reference category. Age (continuous variable and centered 
at 60 years), sex (male and female), socioeconomic status 
(categorized based on SIMD Q 1–5), and number of  co‑morbid 
conditions were entered into the models as categorical variables. 
Baseline HADS‑D score was also entered into the regression 
model as a continuous variable and centered at 11. We visualized 
the results of  the regression with a plot for the mean change 
in HADS‑D against baseline HADS‑D for the four different 
prescription categories.
We calculated the remission rate or the incidence of  having no 
depressive symptoms in year 2 based on an HADS‑D score 
of  < 8 for the patients who were screened in year 1 and noted to 
have depressive symptoms. We used multiple logistic regression 
with the incidence of  having no depressive symptoms in year 
2 at 12 months of  follow‑up as the outcome variable; this was 
used as a measure of  effectiveness for anti‑depressant treatment. 
We used the same predictor variables as described above. We 
report the OR, 95% CI and P values for remission at follow‑up 
for the three groups with different prescribing patterns with 
nonprescribed group taken as the reference category. Smoking 
and alcohol status were not included in any of  the regression 
models due to the large number of  missing values. Analysis was 
carried out using the R statistical software, version 3.0.2.[35]
Sensitivity analysis
The screened population was a subset of  the whole dataset, and 
the majority of  the patients eligible for depression screening 
did not have HADS‑D recorded due to poor uptake of  
depression screening. We compared the demographic features 
and distribution of  clinical risk factors for screened and the 
total population. Interaction of  baseline HADS‑D with the 
anti‑depressant treatment category was tested.
We also repeated the analysis for the subset of  patients with 
HADS‑D ≥ 11 at baseline to assess the impact of  different 
anti‑depressant prescribing pattern for 12 months follow‑up 
duration (continuous, intermittent, and single prescription) in 
patients with moderate to severe depression at baseline, adjusting 
for the confounding factors age, sex, socioeconomic status, and 
number of  co‑morbid conditions as described above.
Results
Sample size and characteristics
Of  the total sample, 35,537 (32.5%) patients with one of  the 
three chronic cardiometabolic diseases had results of  depression 
screening with HADS‑D recorded. n = 7080 (19.9%) of  
the screened population were identified as positives based 
on HADS‑D ≥ 8. 452 patients (6% of  positive depression 
screen at baseline) were started on new anti‑depressant 
treatment (excluding amitriptyline) while 6628 (94%) were 
not prescribed with anti‑depressants. Follow‑up HADS‑D at 
12 months was recorded in 223 (49%) of  patients prescribed 
with anti‑depressants and in 3710 (56%) of  patients not treated 
with anti‑depressants [Figure 1].
Table 1 provides the details of  the demographic characteristics, 
baseline HADS‑D, and health‑related behaviors of  those patients 
with recorded HADS‑D at 12 months follow‑up and compares it 
with those who did not have HADS‑D recorded at follow‑up. The 
table shows that there were no clinically significant differences 
between the two groups in demographic characteristics and 
health‑related behaviors.
Efficacy of  anti‑depressants in patients with 
depression in cardiometabolic disease
Patients who were not prescribed with anti‑depressants had 
the biggest mean change in HADS‑D from baseline with a 
drop of  − 2.20 (95% CIs − 2.58–−1.81) over the 12 months 
follow‑up period. There was no difference in HADS‑D reduction 
between the nonprescribed and the continuously treated 
patients (n = 93). The patients who received intermittent (n = 72) 
or single prescription (n = 58) also saw a reduction in their 
HADS‑D but the drop was significantly less than compared 
to the nonprescribed group. These results remained significant 
after adjusting for age (centered at 60 years), sex, socioeconomic 
status, number of  co‑morbid conditions, and baseline HADS‑D. 
The results are summarized in Table 2.
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Figure 2 shows the mean drop in HADS‑D at 12 months follow‑up 
for the four prescription categories against baseline HADS‑D 
(at the reference level of  other predictors), again showing that 
the drop in HADS‑D was greatest for the nonprescribed group. 
The patients who had continuous anti‑depressants prescriptions 
had a bigger drop in mean HADS‑D when compared to the other 
two prescription categories receiving anti‑depressants.
Effectiveness of anti‑depressants in patients with 
depression in cardiometabolic disease
The remission rate at 12 months follow‑up based on HADS‑D < 8 
was 24% among all patients prescribed with anti‑depressants 
as compared to 37% among all patients not prescribed 
with anti‑depressants. There was no difference in the odds 
of  remission between the continuously prescribed and the 
nonprescribed patients but the odds of  remission were lower in 
patients treated with one prescription or intermittently. These 
results remained significant after adjusting for age (centered 
at 60 years), sex, socioeconomic status, number of  co‑morbid 
conditions, and baseline HADS‑D. These results are summarized 
in Table 3.
Sensitivity analysis
Interaction of  baseline HADS‑D with the anti‑depressant 
treatment category was found to be not significant (P = 0.969). 
The sub‑group analysis for patients noted to have moderate 
to severe depression at baseline (HADS‑D ≥ 11) (n = 2925) 
were analyzed and a repeat HADS‑D at 12 months was 
recorded for 1417 (48.4%) patients. The mean change in 
HADS‑D from baseline for the nonprescribed group − 2.61 
(95% CI − 3.44–−1.79, P < 0.0001) was better than the 
reduction observed in continuously prescribed group 1.09 
(0.08–2.10, P = 0.03), intermittently prescribed group 1.94 
(95% CI 0.71–3.16, P = 0.002) and patients who received 
single prescription 1.69 (95% CI 0.60–2.78, P = 0.002). 
There was no statistical difference between the odds of  
remission for the nonprescribed group when compared with 
that of  the continuously prescribed group (OR 0.93 95% 
CI 0.49–1.76, P = 0.82) and intermittently prescribed group 
(OR 0.47 [95% CI 0.18–1.22, P = 0.12]) but the remission rate 
was significantly lower in patients treated with single script 
(0.21 [95% CI 0.06–0.69, P = 0.01]). These results remained 
significant after adjusting for age, sex, socioeconomic status, 
number of  co‑morbid conditions, and baseline HADS‑D.
Discussion
Summary of findings
In a large community‑based sample of  patients with depression 
and cardiometabolic disease, there was no difference in 
depressive symptoms at 12 months follow‑up, between 
patients prescribed continuously with anti‑depressants and 
those who were not prescribed anti‑depressants. Patients who 
were prescribed anti‑depressants intermittently or issued with 
only one prescription had significantly worse improvement in 
depressive symptoms when compared with those who were 
not prescribed anti‑depressants. These findings persisted after 
adjusting for other possible influencing factors such as age, 
sex, socioeconomic status, number of  co‑morbid conditions, 
and baseline HADS‑D and did not change after repeating the 
Figure 1: Flow chart of patients in the cohort with cardiometabolic disease and positive depression screening (HADS‑D ≥ 8) at baseline. 
Legend: HADS-D = Hospital Anxiety and Depression Score-depressive subscale
Figure 2: The mean change in HADS-D at 12 months follow-up for 
four patient groups with different anti-depressants prescribing pattern, 
in patients with cardiometabolic disease and positive depression 
screening (HADS‑D ≥ 8) at baseline. Legend: HADS‑D = Hospital 
Anxiety and Depression Score-depressive subscale. X-axis = Baseline 
HADS-D score Y-axis = Mean drop in HADS-D at 12 months follow-up
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analysis for a sub‑group of  patients with moderate to severe 
depressive symptoms at baseline.
Strengths and limitations
The study is based on a large community‑based sample reflecting 
real life clinical practice, which is one of  the key strengths of  this 
study. However, there are several limitations, as only a subset of  
the original sample underwent depression screening, and a further 
subset had repeat HADS‑D recorded at 12 months follow‑up. 
Table 1: Comparison of patients with and without 
follow‑up HADS‑D recorded at 12 months 
(HADS‑D ≥8 at baseline)
Follow‑up 
HADS‑D 
recorded (n=3933)
Follow‑up 
HADS‑D not 
recorded (n=3147)
Age (years)
Mean (SD) 67.0 (11.7) 66.8 (13.1)
Median (IQR) 67.0 (59.0, 76.0) 68.0 (58.0, 77.0)
Missing 1 2
Age (years) (%)
18‑44 114 (2.9) 160 (5.1)
45‑64 1519 (38.6) 1162 (36.9)
65‑75 1140 (29.0) 827 (26.3)
76‑90 1158 (29.5) 997 (31.7)
Missing 2 1
Sex (%)
Female 2249 (57.2) 1651 (52.5)
Male 1681 (42.8) 1491 (47.5)
Missing 3 5
Socioeconomic status quintile 
(most deprived=1) (%)
5 414 (10.7) 290 (9.5)
4 333 (8.6) 245 (8.0)
3 407 (10.6) 318 (10.4)
2 729 (18.9) 593 (19.4)
1 1976 (51.2) 1618 (52.8)
Missing 74 83
Number of  co‑morbid 
conditions (%)
Single diagnosis 2826 (71.8) 2269 (72.1)
Two diagnoses 989 (25.1) 792 (25.2)
Three diagnoses 118 (3.0) 86 (2.7)
Missing 0 0
Baseline HADS‑D
Mean (SD) 10.5 (2.6) 10.9 (2.8)
Median (IQR) 10.0 (8.0, 12.0) 10.0 (9.0, 12.0)
Smoking (%)
Current nonsmoker 1120 (55.4) 782 (50.2)
Smoker 903 (44.6) 777 (49.8)
Missing 1910 1588
Alcohol (units/week) (%)
Light 3309 (96.6) 2319 (95.5)
Moderate 95 (2.8) 89 (3.7)
Heavy 20 (0.6) 21 (0.9)
Missing 509 718
Number (missing), mean (SD) and median (IQR) are presented for continuous variables and number (%) 
for a categorical variable. HADS‑D: Hospital Anxiety and Depression Scale and depression; SD: Standard 
deviation; IQR: Interquartile range
Table 2: Efficacy of anti‑depressants in patients with 
depression in chronic disease
Mean change 
(95% CI)
Standardized 
change (95% CI)
P
Change from 
baseline
Nonprescribed 
group
−2.20 (−2.58, −1.81) −0.84 (−0.99, −0.69) <0.0001
Treatment category 
(vs. nonprescribed)
Single prescription 1.22 (0.49, 1.96) 0.33 (0.13, 0.52) 0.0011
Intermittent 
prescriptions
1.87 (1.09, 2.64) 0.50 (0.29, 0.70) <0.0001
Continuous 
prescriptions
0.42 (−0.21, 1.06) 0.11 (−0.06, 0.28) 0.1919
Sex (vs. male)
Female 0.14 (−0.09, 0.38) 0.04 (−0.03, 0.10) 0.2379
Age
5 years increase −0.06 (−0.11, −0.01) −0.02 (−0.03, 0.00) 0.0206
Socioeconomic 
status quintiles 
(most deprived=1) 
(vs. 5th quintile)
4 0.10 (−0.43, 0.63) 0.03 (−0.11, 0.17) 0.7129
3 −0.17 (−0.67, 0.33) −0.05 (−0.18, 0.09) 0.4953
2 −0.02 (−0.46, 0.43) 0.00 (−0.12, 0.11) 0.9467
1 0.38 (−0.01, 0.78) 0.10 (0.00, 0.21) 0.0576
Comorbidity 
(vs. one diagnosis)
Two 0.18 (−0.09, 0.45) 0.05 (−0.03, 0.12) 0.2018
Three 0.23 (−0.47, 0.93) 0.06 (−0.13, 0.25) 0.5220
Baseline HADS‑D −0.39 (−0.43, −0.34) −0.10 (−0.12, −0.09) <0.0001
Linear regression model with change in HADS‑D (mean and standardized) at 12 months follow‑up from 
baseline for patients with positive HADS‑D (≥8) at baseline. Age was centred at 60 years and baseline 
HADS‑D at 11. HADS‑D: Hospital Anxiety and Depression Scale and depression; CI: Confidence interval
Table 3: Effectiveness of anti‑depressants in patients with 
depression in chronic disease
OR (95% CI) P
Treatment category (vs. nonprescribed)
Single prescription 0.51 (0.30, 0.88) 0.0163
Intermittent prescriptions 0.38 (0.21, 0.69) 0.0016
Continuous prescriptions 0.87 (0.58, 1.32) 0.5152
Sex (vs. male)
Female 1.04 (0.90, 1.20) 0.6093
Age
5 years increase 1.03 (0.99, 1.06) 0.1069
Socioeconomic status quintiles 
(most deprived=1) (vs. 5th quintile)
4 1.00 (0.73, 1.37) 0.9997
3 1.27 (0.95, 1.72) 0.1115
2 1.18 (0.90, 1.53) 0.2234
1 0.92 (0.73, 1.17) 0.5104
Comorbidity (vs. one diagnosis)
Two 0.89 (0.75, 1.05) 0.1638
Three 1.05 (0.69, 1.61) 0.8179
Baseline HADS‑D 0.79 (0.76, 0.81) <0.0001
Logistic regression model with remission at 12 months follow‑up from baseline for patients with positive 
HADS‑D (≥8) at baseline OR and 95% CI’s are presented. Age was centred at 60 years and baseline 
HADS‑D at 11. OR: Odds ratio; HADS‑D: Hospital anxiety and depression scale and depression; 
CI: Confidence interval
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Second, there may be significant differences between patients who 
were prescribed anti‑depressants and those who were not, which 
may not be evident from the information available. For example, it 
was not known how many of  the patients with HADS‑D positive 
at baseline were diagnosed with depression by their general 
practitioners, which has been previously found to be a marker 
of  depression severity.[36] We did not have complete information 
on health‑related behaviors such as smoking status, alcohol 
intake, and amount of  physical activity; and no information on 
cardiovascular disease severity or cardiovascular medications. 
These factors are likely to influence the patient’s likelihood of  
having depressive symptoms and subsequent outcomes. Different 
groups of  anti‑depressants may have different results as far as 
efficacy and effectiveness are concerned; we were unable to 
undertake analysis at the level of  individual anti‑depressant group 
prescribed due to lack of  sufficient number of  patients receiving 
anti‑depressant treatment. Finally, we also had no information 
on the use of  psychological therapies in our cohort, both for 
patients who were prescribed and who were not prescribed 
anti‑depressants, which may have influenced the outcome of  
depressive symptoms at 12 months follow‑up.
Comparison with existing literature
The rate of  positive screens ranged from 17% to 21% for those 
with a single condition to 26% for those with multimorbidity.[14] 
This is consistent with rates of  6–22% which have been reported 
in other similar studies of  depression screening.[37]
In patients with depression with CHD, a meta‑analysis based on the 
3 trials and 707 patients,[19‑21] all using selective serotonin reuptake 
inhibitors, showed a standardized difference of  −0.24 (95% 
CI −0.38–−0.09) at short‑term (<6 months) follow‑up favoring 
anti‑depressants against placebo.[17] The reported OR for the 
short‑term remission of  depressive symptoms was 1.80 (95% 
CI 1.18, 2.74) favoring anti‑depressants against placebo,[17] again 
based on the results of  the same three trials.[19‑21] The only trial 
investigating long‑term follow‑up showed that there was no 
difference in remission rates at 18 months between patients 
receiving anti‑depressants and placebo postmyocardial infarction.[22]
In patients with depression in diabetes, a meta‑analysis based on 
seven trials and 306 patients reported a standardized difference 
of  −0.61 (95% CI −0.94–−0.27) at short‑term (<6 months) 
follow‑up favoring anti‑depressants against placebo.[23] The reported 
OR for the short‑term remission of  depressive symptoms was 
2.50 (95% CI 1.20–5.15) favoring anti‑depressants against placebo, 
based on the results of  two trials and 68 patients.[23] In the only 
trial looking at long‑term remission (52 weeks) with depression in 
diabetes, the reported remission rate was 65.8% in patients treated 
with sertraline against 47.9% in patients receiving placebo.[28]
In the meta‑analysis of  patients with poststroke depression based 
on results of  five trials and 410 patients, there was no difference 
in the pooled OR for short‑term remission (<6 months) for 
patients prescribed anti‑depressants OR 0.76 (95% CI 0.51–1.12) 
when compared with control group.[29] The meta‑analysis did not 
report a pooled standardized difference but noted that three out 
of  seven trials reported significant improvement in depressive 
symptoms in short‑term favoring anti‑depressants against 
placebo.[29] Again, there were no studies looking at long‑term 
benefits of  anti‑depressants in poststroke depression.
This is the first study to our knowledge, which reports the efficacy 
and effectiveness of  anti‑depressants from routine clinical practice 
for treatment of  depression with cardiometabolic diseases.
Implications for practice
Improvement in depressive symptoms in patients with the 
cardiometabolic disease at 12 months was not any better in 
patients prescribed with anti‑depressants when compared with 
the nonprescribed group. The patients who were prescribed 
anti‑depressants intermittently or with only a single prescription 
had significantly worse outcomes. These results need to be 
replicated with other datasets, preferably prospectively and in 
randomized controlled trials, to further analyze the usefulness 
of  anti‑depressants in improving depressive symptoms in 
patients with the cardiometabolic disease. Further evaluation 
of  the variation in effects, if  any of  individual subgroups of  
anti‑depressants would also be valuable. Importantly, the role 
of  anti‑depressants in the management of  depression in chronic 
disease merits further research and evaluation.
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